================================================================================
                    EXPORT REGISTRATION AND CERTIFICATES
                    BIOPHARMA INDUSTRIES LIMITED
================================================================================

================================================================================

DOCUMENT 1: CERTIFICATE OF PHARMACEUTICAL PRODUCT (CoPP)

================================================================================

                    CENTRAL DRUGS STANDARD CONTROL ORGANISATION
                    DIRECTORATE GENERAL OF HEALTH SERVICES
                    MINISTRY OF HEALTH AND FAMILY WELFARE
                    GOVERNMENT OF INDIA

--------------------------------------------------------------------------------

CERTIFICATE OF A PHARMACEUTICAL PRODUCT

Certificate Number:     CDSCO/CoPP/2025/5678
Product Reference:      AMOXICILLIN CAPSULES 500mg

--------------------------------------------------------------------------------

This certificate conforms to the format recommended by the World Health
Organization for a Certificate of a Pharmaceutical Product.

--------------------------------------------------------------------------------

EXPORTING (CERTIFYING) COUNTRY: INDIA

1. NAME AND DOSAGE FORM OF PRODUCT

   Product Name:        AMOXICILLIN CAPSULES BP 500mg
   Dosage Form:         Hard Gelatin Capsules
   Strength:            500mg (as Amoxicillin Trihydrate)

2. NAME AND ADDRESS OF MANUFACTURER

   BioPharma Industries Limited
   Plot No. 234-235, MIDC Industrial Area
   Thane-Belapur Road, Rabale
   Thane - 400701, Maharashtra, INDIA

3. PRODUCT STATUS IN INDIA

   (a) Is this product licensed to be placed on the market for use in India?
       YES

   (b) Is the product actually on the market in India?
       YES

4. MARKETING AUTHORIZATION

   Drug License Number:  MH/25D/2013/1234
   Product Approval:     MH/29/2014/567
   Approved On:          February 15, 2014

5. GMP STATUS OF MANUFACTURING FACILITY

   (a) Does the manufacturing plant comply with GMP as recommended by WHO?
       YES

   (b) Date of last inspection: August 5, 2024
       Outcome: Compliant

   (c) WHO-GMP Certificate Number: WHO/GMP/IN/2024/0567
       Valid Until: March 14, 2027

6. APPLICANT FOR CERTIFICATE

   Name:    BioPharma Industries Limited
   Address: Plot No. 234-235, MIDC Industrial Area
            Thane - 400701, Maharashtra

7. REMARKS

   This product is manufactured in accordance with Good Manufacturing
   Practices (Schedule M of Drugs and Cosmetics Rules, 1945) and complies
   with the specifications of British Pharmacopoeia.

--------------------------------------------------------------------------------

                                             [SEAL OF CDSCO]

                                             Sd/-
                                             Drugs Controller General (India)
                                             Central Drugs Standard Control
                                             Organisation
                                             FDA Bhawan, Kotla Road
                                             New Delhi - 110002

Date of Issue: January 15, 2025
Valid Until: January 14, 2026

--------------------------------------------------------------------------------

Note: This Certificate of Pharmaceutical Product (CoPP) must be renewed
annually. Separate CoPPs are issued for each product.

================================================================================

DOCUMENT 2: FREE SALE CERTIFICATE

================================================================================

                    CENTRAL DRUGS STANDARD CONTROL ORGANISATION
                    GOVERNMENT OF INDIA

--------------------------------------------------------------------------------

FREE SALE CERTIFICATE

Certificate Number:     CDSCO/FSC/2025/1234

--------------------------------------------------------------------------------

This is to certify that the following pharmaceutical products manufactured by:

Manufacturer:           BioPharma Industries Limited
Address:                Plot No. 234-235, MIDC Industrial Area
                        Thane - 400701, Maharashtra, INDIA

Are freely sold in India without any restriction:

S.No  Product Name                      Drug License Approval No.
--------------------------------------------------------------------
1.    Amoxicillin Capsules 250mg        MH/29/2014/566
2.    Amoxicillin Capsules 500mg        MH/29/2014/567
3.    Azithromycin Tablets 250mg        MH/29/2018/234
4.    Azithromycin Tablets 500mg        MH/29/2018/235
5.    Metformin HCl Tablets 500mg       MH/29/2014/890
6.    Metformin HCl Tablets 850mg       MH/29/2014/891
7.    Amlodipine Tablets 5mg            MH/29/2014/123
8.    Amlodipine Tablets 10mg           MH/29/2014/124
9.    Cefixime Tablets 200mg            MH/29/2017/345
10.   Ciprofloxacin Tablets 500mg       MH/29/2015/456

The manufacturer holds valid Drug Manufacturing License No. MH/25D/2013/1234
issued by Food and Drug Administration, Maharashtra.

                                             Sd/-
                                             Deputy Drugs Controller (India)

Date of Issue: January 15, 2025
Valid Until: January 14, 2026

================================================================================

DOCUMENT 3: EXPORT COUNTRY REGISTRATIONS

================================================================================

BioPharma Industries has registered products in the following countries:

AFRICAN MARKETS:

Country         Regulatory      Products    Registration   Status
                Authority       Registered  Valid Until
--------------------------------------------------------------------
Kenya           PPB             12          2029           Active
Nigeria         NAFDAC          10          2028           Active
Tanzania        TFDA            8           2027           Active
Uganda          NDA             6           2027           Active
Ghana           FDA Ghana       7           2028           Active
Ethiopia        EFDA            5           2026           Active
South Africa    SAHPRA          3           2029           Active

ASIAN MARKETS:

Country         Regulatory      Products    Registration   Status
                Authority       Registered  Valid Until
--------------------------------------------------------------------
Philippines     FDA Phil        8           2028           Active
Vietnam         DAV             6           2027           Active
Sri Lanka       NMRA            10          2029           Active
Myanmar         FDA Myanmar     4           2026           Active
Cambodia        DDF             5           2027           Active

LATIN AMERICAN MARKETS:

Country         Regulatory      Products    Filing Status
                Authority       Filed
--------------------------------------------------------------------
Brazil          ANVISA          5           Filed Q3 FY26
Mexico          COFEPRIS        3           Planned Q4 FY26

MIDDLE EAST:

Country         Regulatory      Products    Registration   Status
                Authority       Registered  Valid Until
--------------------------------------------------------------------
Yemen           SBDMA           6           2027           Active
Iraq            MOH Iraq        4           2026           Active

================================================================================

SAMPLE REGISTRATION CERTIFICATE (KENYA)

================================================================================

                    PHARMACY AND POISONS BOARD
                    MINISTRY OF HEALTH
                    REPUBLIC OF KENYA

--------------------------------------------------------------------------------

CERTIFICATE OF REGISTRATION

Registration Number:    PPB/PH/KE/2019/0567

Product Name:           AMOXIBIO 500
                        (Amoxicillin Capsules BP 500mg)

Manufacturer:           BioPharma Industries Limited
                        Thane, Maharashtra, India

Local Representative:   East Africa Pharma Limited
                        Nairobi, Kenya

Date of Registration:   March 15, 2019
Valid Until:            March 14, 2029

Classification:         Prescription Only Medicine (POM)

This product has been registered for sale in Kenya and meets the quality,
safety, and efficacy requirements of the Pharmacy and Poisons Board.

                                             Sd/-
                                             Registrar
                                             Pharmacy and Poisons Board
                                             Nairobi, Kenya

================================================================================

DOCUMENT 4: EXPORT PERFORMANCE

================================================================================

EXPORT REVENUE BY REGION (FY 2024-25):

Region                  Revenue (Rs. Cr)    Percentage
------------------------------------------------------
Africa                  65.50               58.5%
Asia                    35.20               31.4%
Middle East             8.30                7.4%
Latin America           3.00                2.7%
------------------------------------------------------
TOTAL                   112.00              100%

TOP 5 EXPORT MARKETS (FY 2024-25):

Country                 Revenue (Rs. Cr)
----------------------------------------
1. Kenya                28.50
2. Nigeria              18.20
3. Philippines          15.80
4. Vietnam              12.40
5. Sri Lanka            10.60

EXPORT PROJECTIONS:

FY 2025-26:            Rs. 135 Crores (20% growth)
FY 2026-27:            Rs. 175 Crores (30% growth - with US market entry)
FY 2027-28:            Rs. 250 Crores (43% growth)

================================================================================

DOCUMENT 5: US FDA STATUS

================================================================================

US FDA ESTABLISHMENT REGISTRATION:

FEI Number:             3008765432
DUNS Number:            86-543-2109
Registration Status:    Registered (not yet inspected)
US Agent:               PharmaReg Services Inc., New Jersey

ANDA FILING STATUS:

Product                           ANDA Number    Status          Expected
                                                                 Approval
------------------------------------------------------------------------
Metformin HCl ER Tablets          ANDA 215XXX   APPROVED        -
500mg/750mg/1000mg                              (June 2024)

Amlodipine Besylate Tablets       ANDA 216XXX   APPROVED        -
2.5mg/5mg/10mg                                  (Jan 2025)

Atorvastatin Calcium Tablets      ANDA 217XXX   Under Review    Q2 FY26
10mg/20mg/40mg/80mg

Omeprazole DR Capsules            ANDA 218XXX   Under Review    Q3 FY26
20mg/40mg

Losartan Potassium Tablets        ANDA 219XXX   Tentative       Post-
25mg/50mg/100mg                                 Approval        exclusivity

Lisinopril Tablets                ANDA 220XXX   Tentative       Post-
5mg/10mg/20mg/40mg                              Approval        exclusivity

Gabapentin Capsules               ANDA 221XXX   CRL Received    Q4 FY26
100mg/300mg/400mg                               (Amendment
                                                filed)

Metoprolol Succinate ER           ANDA 222XXX   Filed           FY 2026-27
Tablets 25mg/50mg/100mg/200mg                   (Sep 2025)

CRL = Complete Response Letter (deficiency to be addressed)

US MARKET STRATEGY:

1. Focus on high-value generic molecules with limited competition
2. Priority to resolve Gabapentin CRL and convert tentative approvals
3. Prepare for US FDA facility inspection (expected FY 2025-26)
4. Build US distribution partnerships

================================================================================

DOCUMENT 6: EXPORT INCENTIVES AVAILED

================================================================================

1. RODTEP (Remission of Duties and Taxes on Exported Products)
   - Rate: 0.5% - 4.3% depending on product
   - FY 2024-25 benefit: Rs. 2.8 Crores

2. DUTY DRAWBACK
   - On import content of exported products
   - FY 2024-25 benefit: Rs. 1.5 Crores

3. ADVANCE AUTHORIZATION
   - Duty-free import of inputs for export production
   - FY 2024-25 authorization: Rs. 15 Crores

4. EXPORT PROMOTION CAPITAL GOODS (EPCG) SCHEME
   - Duty-free import of capital goods against export obligation
   - EPCG license for laboratory equipment: Rs. 2 Crores

================================================================================
                    END OF EXPORT REGISTRATION CERTIFICATES
================================================================================
